AbTx, an innovative biotechnology company in biotherapy

AbTx is a biotechnology company that designs personalized medicine biotherapies in oncology, based on antibody-drug conjugates (ADCs). Antibody-drug conjugates have been called “biological missiles” because of their ability to selectively deliver cytotoxic agents to tumor cells, potentially improving the therapeutic index of small cytotoxic molecules (such as those used in chemotherapy). AbTx’s mission is to offer differentiated ADCs to patients with significant unmet needs.

More effective and better tolerated targeted chemotherapy

These conjugated “drugs” are cytotoxic agents that target tumors. More precisely, this tumor targeting is mediated by an antibody, which specifically recognizes cancer cells. A potent anti-tumor therapeutic agent is conjugated to this antibody. This conjugated drug, called an antibody-drug conjugate (ADC), thus spares healthy tissues. By enabling the targeted delivery of potent therapeutic agents to tumors while minimizing systemic toxicity, antibody-drug conjugates (ADCs) have demonstrated increased efficacy, a wider therapeutic window, and improved pharmacokinetics compared to traditional chemotherapies.

ADCs, a dynamic and rapidly growing field

After decades of investment, ADCs are booming, as evidenced by their use as first-line therapy and their integration into drug combinations, particularly in immunotherapy. However, their efficacy remains limited against solid tumors, with only six treatments currently approved.

AbTx is inventing the next generation of ADCs via its Therano-Stick ^TM technology platform.

The optimal use of antibody-drug conjugates (ADCs) in clinical practice requires overcoming current obstacles, primarily limitations in their tumor penetration capacity when targeting solid tumors. To address this suboptimal tumor penetration issue, Therano-Stick ^™ technology enables the generation of miniaturized antibody fragment conjugates (FDCs). AbTx is thus developing smaller and more precise antibody fragment conjugates (FDCs). This approach allows for up to 10 times faster penetration of solid tumors and reduces exposure to healthy tissues, while maintaining the potency of conventional ADCs. The technology is based on an enzyme, microbial transglutaminase (mTG), which attaches active molecules in a targeted and stable manner to various antibody formats (full-length or Fab, scFv, VHH fragments), paving the way for more effective and better-tolerated treatments.

To offer differentiated ADCs to patients with significant unmet needs to date

AbTx is focusing its efforts on pancreatic cancer, one of the most aggressive and difficult to treat, where the five-year survival rate is less than 11%. Without new therapies, it could become the second leading cause of cancer death worldwide by 2030. AbTx is developing a portfolio of FDCs targeting a novel target (“ Tx-101, first-in-class ”) and another known target (“Tx-104, best-in-class”) to treat pancreatic cancer, with potential applications in other indications. The development of these programs paves the way for more effective and targeted treatments for pancreatic cancer. AbTx also has the ability to explore new targets through its discovery platform.

To exploit and enhance the potential applications of our Therano-Stick™ technology

Therano-Stick™ technology could also be used for innovative antibody conjugates in molecular radiotherapy.

Developing differentiated ADCs, investment opportunities

At the recent ESMO 2025 congress , substantial progress in ADCs across several tumor types was reported. Beyond clinical data, a key observation was made regarding the attractiveness criteria sought by investors, including differentiated ADCs.

These opportunities to develop differentiated ADCs are linked to (1) new platform technologies, (2) new targets with validated biology, and (3) technologies related to industrial applications (CDMO). These three criteria are fully aligned with AbTx’s expertise, driven by a founding team with complementary skills: Dr. Meddy EL ALAOUI (CEO), PhD in biochemistry and expert in conjugation; Dr. Boris VUILLERMOZ (CTO), PhD specializing in antibody fragment design through molecular engineering; and Dr. Claudine VERMOT-DESROCHES (CSO), PhD in immunology and expert in oncological immunotherapy research.

We thank our initial investors, partners, and team for making AbTx a key player in innovation within the field of differentiated ADCs. To continue and accelerate the development of its portfolio of innovative miniaturized antibody-drug conjugates and the commercialization of applications for its Therano-Stick™ technology, AbTx aims to raise €400,000.